BioSpace News Archive

OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 first quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, May 5, 2021.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, May 3, 2021 at 8:30 am Eastern Time, the Company will host a webcast and conference call to present results from the 30 mg/kg arm of the MOMENTUM study, a multiple-ascending dose clinical trial of SRP-5051 for the treatment of Duchenne muscular dystrophy

Spero Therapeutics, Inc. announced that on April 30, 2021, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 28,600 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan.

Relay Medical Corp. (CSE: RELA) (OTC: RYMDF) (FSE: EIY2) (“Relay” or the “Company”), a developer of technological innovation, is pleased to provide an update on ongoing activities related to the Company’s commercial and development activities.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on Apr. 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 4 individuals hired by Sarepta in April 2021.

In DAPA-CKD Phase III trial, FARXIGA demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end stage kidney disease and cardiovascular or renal death

Vifor Fresenius Medical Care Renal Pharma announced positive results from a phase-III study in China, evaluating the efficacy of Velphoro® compared to sevelamer carbonate in lowering and maintaining serum phosphorus in adult Chinese patients with chronic kidney disease on dialysis after 12 weeks of treatment.

The global prosthetics and orthotics market is anticipated to gain growth with the rising incidence of osteosarcoma.

Transparency Market Research has published a new report titled, ‘Global Endosurgery Devices Market’. According to the report, the global endosurgery devices market was valued at ~US$ 9 Bn in 2018 and is projected to expand at a CAGR of ~4% from 2019 to 2027.

Biosimilars can be defined as a biologic medical product, which is considered to be similar to already approved biologic.